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Treatment-resistant depression is associated with signiﬁcant disability and, due to its high prevalence, results in substantive
economic and societal burden at a population level. The objective of this study is to synthesize extant literature on approaches
currently being applied to understand and address this condition. It is hoped that the ﬁndings can be used to inform practitioners
and guide future research. A scoping review of the scientiﬁc literature was conducted with ﬁndings categorized and charted
by underlying research paradigm. Currently, the vast majority of research stems from a biological paradigm (81%). Research
on treatment-resistant depression would beneﬁt from a broadened ﬁeld of study. Given that multiple etiological mechanisms
likely contribute to treatment-resistant depression and current eﬀorts at prevention and treatment have substantial room for
improvement, an expanded research agenda could more eﬀectively address this signiﬁcant public health issue.
1.Introduction
Of the population receiving treatment for depression, a
large proportion is not responding adequately to current
treatment approaches, with an estimated 50–70% described
as treatment resistant [1, 2]. A consistent and commonly
accepteddeﬁnitionfortreatment-resistantdepression(TRD)
remains elusive. Greden [1] argues that remission should
be the ultimate goal of treatment and absence of remission
should be the criterion used for determining the presence
of TRD. Berlim and Turecki have noted over 10 diﬀerent
deﬁnitions for TRD in the specialized literature [3, 4].
H o w e v e r ,i nas y s t e m a t i cr e v i e wo fr a n d o m i z e dt r i a l s( n =
47), they report a general consensus within the literature
deﬁning clinically signiﬁcant TRD as “an episode of major
depression (that) has not improved after at least two
adequate trials of diﬀerent classes of (antidepressants)” (n =
26)[4,page703].TheauthorsfurtherarguethatTRDshould
be viewed on a continuum ranging from partial response to
completetreatmentresistanceasopposedtoanallornothing
phenomenon. They point out that an inadequate response to
treatment should constitute failure to reach remission, and
that future studies should employ this criterion as the “gold
standardoutcome,”aconclusionthatparallelsGreden’swork
[1].
Fava deﬁnes TRD as a failure to achieve remission
following an adequate trial of antidepressant therapy [5].
This deﬁnition diﬀers from that proposed by Berlim and
Turecki in that it does not necessitate two adequate trials of
antidepressant treatment [3, 4]. Like other TRD researchers
[1, 3, 4], Fava stresses the importance of remission as
the treatment goal, noting that individuals with residual
depressive symptoms show poorer long-term outcomes and
increased relapse risk [6], a ﬁnding supported by other
research in the ﬁeld [7, 8].
Given the inconsistency in deﬁnition, it is diﬃcult to
accurately measure the prevalence or disease burden associ-
ated with TRD. However, despite the conceptual limitations,
the burden of illness associated with TRD is considered to
be substantial. TRD is posited to be responsible for the
greatest burden associated with depressive disorders [1]. The
suﬀering and disability associated with chronic, unremitting2 Depression Research and Treatment
depressive illness is profound. In an eﬀort to better quantify
the economic burden associated with TRD, Greenberg and
colleagues conducted a study of an employed population
to identify the diﬀerential health care costs associated with
nonresistant depression, and TRD [9]. Health care costs
associated with TRD employees were found to be more than
doublethecostsassociatedwithemployeeswithnonresistant
depression and almost quadruple the costs associated with
employees from a random sample. Greden argues that the
disease burden associated with TRD is unacceptably large
and represents a signiﬁcant public health issue requiring a
paradigm shift towards prevention, early intervention, and
adequate treatment [1].
The objective of this scoping review was to examine the
rangeofapproachesbeingappliedtounderstandandaddress
T R Di na ne ﬀort to guide research and practice in this area.
A scoping review is a relatively new research approach which
allows for quick and systematic identiﬁcation of the breadth
of literature in a subject area of interest. This methodology,
which aims to illuminate the scope or extent of literature in
a particular area, can be contrasted with systematic reviews
which have a narrower focus and seek to answer well-deﬁned
research questions from the available literature, while also
encompassing a component to determine the quality of
research reviewed. The York scoping review methodology
outlined by Arksey and O’Malley [10] describes scoping
reviews as having at least four potential functions: to map
the current state of literature in an area of interest, to
determine the value or feasibility of conducting a systematic
review, to summarize and disseminate research ﬁndings
to an audience (e.g., policy makers, clinicians, consumers,
etc.), and ﬁnally, to identify gaps where further research is
required. The scoping review process involves ﬁve essential
steps: (1) determining the research question, (2) identifying
relevant studies, (3) selecting studies, (4) charting data,
and (5) collating, summarizing, and reporting results [10].
This scoping review utilized the York framework to survey
the literature to identify the current state of evidence
surrounding the approaches and paradigms being utilized to
understand and address TRD.
2.MaterialsandMethods
A systematic search of the literature was undertaken util-
izing six electronic databases (Academic Search Pre-
mier, CINAHL, Medline, PsycArticles, PsychInfo, and
Health Source). Keywords to identify literature related
to TRD included: “treatment-resistant and depression,”
“refractory and depression,” “therapy-resistant and depres-
sion,” “treatment-resistant and depression and social,”
“treatment-resistant and depression and nonpharmaco-
logical,” “treatment-resistant, and depression and novel,”
“medication-resistant and depression,” “treatment-resistant
and depression and burden,” “treatment-resistant and
depression and public health.” Resulting titles (n = 2392)
were scanned to identify articles that met the inclusion
criteria which included research articles related to unipolar
TRD amongst the adult population (ages 18 and 65) with
English language abstracts available, and publication dates
from 2005–2010. Letters to the editor and responses to
articles were excluded. This process produced a total of
345 articles that were exported to reference management
database, Mendeley, for analysis. These papers were then
hand-searched and the data charted by theme. Thematic
classiﬁcation was carried out by the lead author, with
decisions reviewed by second author. Where discrepancies
in classiﬁcation existed, the article in question was discussed
and agreement reached between authors. These themes
inform the structure of the following results.
3. Results
The vast majority of the literature (n = 277; 80%) focused
o nt r e a t m e n tw i t hm u c hl e s sa t t e n t i o nd i r e c t e dt o w a r d
identifying the causal factors that contribute to treatment
resistance (n = 33; 10%) or discussing conceptualizations
of the illness, current treatment trends, deﬁnitional and
treatmentissues,andidentifyingresearchgaps(n=36;10%).
The literature identiﬁed through the scoping review was
classiﬁed thematically by underlying paradigm as biological
(n = 281; 81%), psychological (n = 11; 3%), social (n = 2;
1%), multiple or combined paradigms (e.g., biological and
psychological therapies used simultaneously, n = 6; 2%), and
other (n = 45; 13%). We describe ﬁndings classiﬁed by each
paradigm or combination below.
3.1. Biological Paradigm. Of the articles identiﬁed, 81% (n =
281)fellwithinthebiologicalparadigm.Theliteratureinthis
theme was further classiﬁed by focus as pharmacotherapy (n
= 145), neurostimulation, and neurosurgical interventions
(e.g., repetitive transcranial magnetic stimulation (rTMS),
vagus nerve stimulation, deep brain stimulation, electro-
convulsive therapy, and neurosurgery, n = 104), biologically
based causal mechanisms (n = 30), and other (n = 2).
The psychopharmacology literature focuses largely on
determining eﬃcacious augmentation strategies for those
who have not achieved remission following antidepres-
sant monotherapy. Augmentation is a common approach
employed in the treatment of TRD and is endorsed by
various TRD treatment staging models including the Thase
and Rush Model of Staging Treatment Resistance, the
Massachusetts General Hospital Staging Method, and the
European Staging Method [3, 5]. While many of the articles
represent reviews or discussions surrounding augmentation
strategies, others provide evidence of the eﬃcacy of speciﬁc
augmentation combinations. For example, Anderson et al.
[11]c o n d u c t e das m a l l( n = 24) open-label trial to explore
the eﬃcacy of atypical antipsychotics (i.e., quetiapine) as
an augmentation strategy for patients diagnosed with TRD
who were currently taking a monoamine reuptake inhibitor.
These authors conclude that quetiapine augmentation may
be helpful for patients with TRD, but acknowledge that
placebo-controlled studies with larger sample sizes are
required. In fact, the absence of large, controlled trials of
speciﬁc augmentation strategies is a concern identiﬁed in a
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literature review of augmentation strategies and point out
a current shortcoming within the literature that although
t h e r ea r en u m e r o u ss t u d i e so fd i ﬀerent pharmaceutical aug-
mentation strategies, to date, few represent large, controlled
trials in which clinicians can have conﬁdence in the ﬁndings.
The types of medications studied for use in augmentation
therapy of TRD include mood stabilizers (e.g., lithium, lam-
otrigine), monoamine oxidase inhibitors, tricyclic antide-
pressants, thyroid hormones (e.g., T3), vitamin supplements
(e.g., zinc), antipsychotics (e.g., quetiapine, olanzapine,
risperidone), nicotinic antagonists, antibiotics (e.g., D-
cycloserine), psychostimulants (e.g., methylphenidate), opi-
ates (e.g., buprenorphine), and anaesthetics (e.g., ketamine).
Like the pharmacotherapy literature, much of the litera-
tureonotherbiologicaltherapiesfocusesondeterminingthe
eﬃcacyofaspeciﬁctreatment,orcombinationoftreatments,
with a small body of research exploring this intervention on
a more micro level seeking to identify the pathophysiologic
changes associated with these interventions. The eﬃcacy
studies conducted on rTMS report primarily promising
results. In a systematic review and meta-analysis of rTMS
for TRD, Lam and colleagues [13] identiﬁed 24 controlled
trials assessing the eﬃcacy of active versus sham rTMS and
conclude that rTMS demonstrates positive results. However,
the authors argue that further studies are required given
limitations resulting from relatively small eﬀect sizes, short
treatment periods (i.e., 1–4 weeks), and lack of systematic
followup after completion of the intervention period. Taking
a more microlevel approach to exploring rTMS, Kito et
al. [14–17] have undertaken a number of studies exploring
the brain regions associated with rTMS and antidepressant
response. For example, in a 2008 study, Kito and colleagues
[14] investigated the neuroanatomical changes associated
with the application of high frequency rTMS. Using single-
photon emission computed tomography, the researchers
produced brain imaging that lead them to conclude that the
antidepressanteﬀectsofrTMSare,inpart,aresultofchanges
in the function of both the left dorsolateral prefrontal cortex
and the limbic-paralimbic regions of the brain.
Similarly, the studies on vagus nerve stimulation, deep
brain stimulation, electroconvulsive therapy, and neuro-
surgery were largely focused on determining the safety and
eﬃcacy of these treatment approaches. A small number
of the studies that addressed these nonpharmacological
biological approaches also looked at the eﬃcacy of combin-
ing these treatments with each other (e.g., [18, 19]). For
example, Burke and Husain [18] explored the implications
of combined vagus nerve stimulation and electroconvulsive
therapy. The authors conclude that this novel approach
to addressing TRD is safe; the two therapies can be used
together. Further, the authors suggest that both of these
interventions can be employed to address diﬀerent clinical
manifestations of TRD: vagus nerve stimulation for treat-
ment of chronic depressive symptoms and electroconvulsive
therapy for worsening depressive symptoms and mainte-
nance. Many of the studies categorized as neurostimulation
and neurosurgical interventions demonstrated inconsistent
outcomes, had small sample sizes, or were limited to brief
follow-up periods.
The majority of studies classiﬁed within the biologi-
cal paradigm addressed therapeutic intervention trials in
humans (n = 251). However, a number of other studies
(n = 30) sought to identify the biologically based causal
factors associated with TRD. These investigations included
human brain imaging studies as well as research seeking to
detect various biological markers or mechanisms involved
in the experience of TRD (e.g., lower plasma levels of
Coenzyme Q10 [20], lower cerebral spinal ﬂuid levels of
substance P [21], impaired glucocorticoid receptor function
[22]). In 2009, Juruena and colleagues [23] published the
resultsofaprospectivestudyexploringthefunctioningofthe
hypothalamic-pituitary-adrenal (HPA) axis in patients with
depression. The researchers were able to demonstrate that
patients with depression experience HPA axis overactivity
and, further, that the negative feedback system that typically
controls HPA axis activity is impaired in patients experi-
encing TRD. Given these ﬁndings, the authors suggest that
neuroendocrine dysfunction is a reliable marker for poor
treatment response in patients presenting with depression.
3.2. Psychological Paradigm. Approximately 3% (n = 11) of
the articles identiﬁed through this scoping review could be
classiﬁed as stemming from a psychological paradigm. This
literature consisted predominantly of studies exploring the
applicationofcognitivebehaviouraltherapyinthetreatment
of TRD (n = 7). However, there is a limited literature on
more novel psychological approaches including mindfulness
and dialectical behavioural therapy. Many of the articles
falling into this theme are discussion papers as opposed
to empirical studies. However, the limited literature that
does provide data on the eﬃcacy of psychotherapy for TRD
reports favourable outcomes. For example, Watkins and
colleagues [24] conducted a study of rumination-focussed
cognitive behavioural therapy. Rumination is identiﬁed as
a key factor in the onset and maintenance of depressive
symptomology. In this small study (n = 14), patients
with TRD were provided with up to 12 sessions of one-
on-one cognitive behavioural therapy. The authors report
that the intervention resulted in signiﬁcant reductions in
symptomology, with 50% of their participants achieving
remission. In another study exploring cognitive behavioural
therapy for patients experiencing TRD, the researchers took
a group therapy approach, which also demonstrated positive
outcomes. Matsunaga et al. [25] explored the eﬀectiveness
of group-based cognitive behavioural therapy addressing
psychosocial functioning and depressive symptomology
amongst patients with “mild” TRD. Participants in this study
(n = 38) attended 12 sessions of cognitive behavioural group
therapy over a 12-week period. Following the intervention,
participants demonstrated signiﬁcant reductions in depres-
sive symptomology and enhanced psychosocial functioning.
Further, the intervention appeared to produce sustainable
improvements; participants who completed the 12-month
followup measures (n = 20) continued to demonstrate
improved psychosocial and mood outcomes.4 Depression Research and Treatment
3.3. Social Paradigm. This scoping review identiﬁed only
two articles classiﬁed as stemming from a social paradigm.
This small literature describes various social factors found
to be associated with TRD including: poor baseline ﬁnancial
status, rural area of residence (which was proposed to
inﬂuence TRD through lower levels of neighbourhood and
personal socioeconomic status, and a greater likelihood of
receiving less than adequate drug treatment), lower levels
of psychosocial functioning [26], and exposure to serious
life events (speciﬁcally, job loss, and ﬁnancial distress) [27].
However, even within this limited literature, there are incon-
sistent ﬁndings. For example, while Amital and colleagues
[27] report speciﬁc serious life events to be associated with
TRD, Viinam¨ aki et al. [26] found no relationship between
serious life events and this illness.
3.4. Multiple Paradigms. In addition to the literature that
could be clearly classiﬁed as biological, psychological or
social in paradigm, there was also a very limited research
exploring a combination of these approaches (n = 6). This
literature includes ﬁve primary studies and one discussion
paper, all of which focus on the eﬀectiveness of combining
medications with psychotherapy (i.e., cognitive behavioural
therapy or interpersonal therapy). This literature indicates
that utilizing a combination of biological and psychological
approaches results in superior treatment outcomes as com-
pared to single mode approaches. Schramm and colleagues
[28] conducted a study on an inpatient psychiatric unit
in which they randomized patients (n = 45) to either a
treatment arm, in which participants received medication
therapy combined with interpersonal psychotherapy (utiliz-
ingacombinationofindividualandgroup-therapyformats),
or a control arm, in which participants received medica-
tion therapy and clinical management (i.e., usual care).
Following the ﬁve-week intervention, patients who received
interpersonal psychotherapy in combination with pharma-
cotherapy showed statistically signiﬁcant improvement over
those who received clinical management in combination
with medication therapy (remission rates amongst the psy-
chotherapy group were 67% versus 32% among the clinical
management group). Further, at 12-month follow up, only
7% of the pharmacotherapy/psychotherapy participants had
experienced a depressive relapse compared with 25% of the
pharmacotherapy/clinical management group participants.
Althoughtheﬁndingsofthisstudysuggestthatinterpersonal
psychotherapy leads to enhanced treatment outcomes over
usual care, the authors note limitations to their study
including unequal levels of therapeutic attention between
participant groups and the inpatient status of their partici-
pants (limiting generalizability of the intervention ﬁndings
to this patient subgroup). In another study exploring the
combination of psychotherapy and pharmacotherapy, Wiles
and colleagues [29] conducted a feasibility study of cognitive
behavioural therapy in combination with pharmacotherapy
for primary care patients experiencing TRD, noting that
to date, no randomized controlled trials of this type of
intervention have been conducted. The researchers report
that their study demonstrates that primary care patients
with TRD are agreeable to participating in psychotherapy
in combination with pharmacotherapy and advocate for
large-scale randomized controlled trials to demonstrate the
eﬀectiveness of this multimodal approach.
3.5. Other. In addition to the papers that we were able to
categorize as drawing from a particular paradigm, there were
an u m b e ro fp a p e r s( n = 45) which did not ﬁt within this
classiﬁcationsystem.Thesemanuscriptsrepresentdiscussion
papers surrounding various topics related to TRD including:
deﬁnitional concerns (e.g., [3, 4, 30]), current treatment
trends (e.g., [31, 32]), overviews of the illness and suggested
“next steps” (e.g., [31]), descriptions of the work of select
large-scale studies (e.g, [33, 34]), and clinical issues and
treatment staging models (e.g., [35, 36]).
4. Discussion
Despite acknowledgement that “depression is the product of
a complex interaction between biological, psychological and
social elements” [37, page 5], this scoping review found that
the study of TRD has been focused primarily on biologically
based treatments.
4.1. Biological Dominance. The biological paradigm has
dominated mental health research and practice for the last
several decades [38]; resulting in a situation Cohen describes
as biological reductionism—a skewed view of mental health
and illness that does not adequately consider the social or
psychological aetiology of these disorders [39]. The prepon-
derance of the biological approach is apparent in the TRD
research literature and appears to inﬂuence the proposed
deﬁnitions, treatment staging, treatment approaches, and
types of research being conducted. This is exempliﬁed by
the currently proposed deﬁnitions for TRD which are based
on failure to respond to antidepressant medication. This
produces a tautology in which the presence or absence of
TRD is based solely on response to a biological treatment.
These proposed deﬁnitions fail to adequately acknowledge
the complexity of this illness and the limitations of this
approach.
Pharmacotherapy was a central focus of the research
literature, with 52% of the articles within the biological
paradigmreportingonthistreatmentapproach.Itispossible
that the overreliance on pharmacotherapy as an approach to
TRD may be limiting the eﬀectiveness of current treatment
eﬀorts.
4.2. Seeking a Balanced Approach. A signiﬁcant gap in the
current literature is research seeking to identify the causal
factors associated with TRD from a social or psychological
perspective. Without epidemiological or social science stud-
ies addressing this knowledge gap, we lack an understanding
of who is at risk for TRD; evidence that is necessary to
inform the development of more eﬀective prevention and
treatment strategies. However, from the research that has
been conducted in this area, it is clear that a more balanced
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one that acknowledges and targets the complex and diverse
aetiology of this illness. For example, within the limited
research exploring combination approaches to TRD, the
ﬁndings indicate that broader approaches result in enhanced
treatment outcomes [40, 41].
Given the multifaceted causal mechanisms underlying
TRD, we hypothesize that the most eﬀective treatment
approaches would be equally complex and include inter-
ventions that address the diverse factors contributing to
this debilitating illness. Interestingly, interdisciplinary and
multimodal approaches to TRD remain novel, as evidenced
by the very limited work identiﬁed in this area. For example,
although psychotherapy has been established in the clinical
guidelinesliteratureasaneﬀective,evidence-basedtreatment
for depression [42]; research exploring the utility of psycho-
logical approaches for TRD remains extremely limited.
Current eﬀorts to address TRD represent a “downstream
approach”—seeking to address the problem once it is already
causing substantial distress and disability. The downstream
approach is common in health care, but is not necessarily the
most eﬀective strategy for reducing incidence and prevalence
of disorder. With the growing prevalence of depression
and TRD, and the resulting burdens, research identifying
appropriate “upstream approaches” is needed. Upstream
approaches to health target the root causes of the issue and
help to prevent incidence of illness. Research identifying
the various social factors contributing to this disorder is
necessary. This would allow for interventions and policies
that address the social determinants of depression and foster
mental health. The limited research that is available indicates
that social factors are predictive of treatment-resistance
[26]. One could imagine that if members of the TRD
population are experiencing adverse life situations related
to socioeconomic status (e.g., poor working conditions,
unemployment, low levels of education, etc.), gender (e.g.,
violence, stress related to competing life roles, sexism, etc.),
or other social factors (e.g., loss of a loved one, ﬁnancial
insecurity, etc.) that attention to these issues may contribute
to improved health outcomes, and better prevention and
treatment approaches in the future.
Our lack of knowledge surrounding the various causal
factors associated with this illness should be of signiﬁcant
concern to policy makers, researchers, health professionals,
andthegeneralpublic.Withoutabetterunderstandingofthe
disorder, the health, social, and economic burdens associated
with TRD will continue to constitute a substantive public
health problem. Further research encompassing broader
perspectives and approaches is necessary if we hope to make
progress in reducing the incidence and prevalence of TRD.
4.3. Deﬁnitional Diﬃculties and Skewed Staging Models. In
addition to the problems stemming from an overemphasis
on biological paradigms, a signiﬁcant barrier to better
addressing TRD is the lack of a universally accepted deﬁ-
nition. The absence of a consistent deﬁnition of TRD has
been problematic in the literature in that it has led to
diﬃculties in accurately and consistently measuring related
constructs. However, these issues may actually serve as an
opportunity for researchers, clinicians, and policy makers to
come together in an eﬀort to create necessary change. Eﬀorts
to expand the deﬁnition of TRD to more accurately reﬂect
theexperienceandtocapturetherapiesbeyondthebiological
paradigm are needed.
In addition to issues surrounding the biological domi-
nance of current research and treatment approaches, the lack
of research evidence exploring the causal factors associated
with TRD, and the inconsistent deﬁnitions proposed for the
illness, there are challenges associated with the detrimentally
narrow focuswithin the treatmentstaging models employed.
Fava acknowledges the “pharmaco-centric” approach to
TRD, and the need to incorporate other evidence-based
therapies, including psychotherapy, into the depression
treatment approach [5]. However, despite this claim, non-
biological therapies do not appear in the most common
treatment staging models [43]. Future research and practice
guidelines must acknowledge the important role of non-
pharmacologic interventions in the treatment of depression,
and incorporate these approaches into a widely accepted
diagnostic deﬁnition and treatment algorithm for TRD.
5. Conclusions
Current treatment approaches to depression are not eﬀective
in producing remission in a large proportion of those
aﬀected by this illness, resulting in a high prevalence of
TRD,aformofdepressionwhichproducessigniﬁcantdisease
burden. Further, despite evidence that depression results
from the interaction of biological, psychological, and social
factors, the scientiﬁc literature addressing TRD remains
unbalanced,withlittleresearchfocusingonthepsychological
or social aspects of the illness. This scoping review highlights
the need to expand the scope of research being conducted
in order to decrease the substantial burden associated with
TRD and improve health outcomes for those experiencing
this debilitating illness.
Acknowledgments
Financialsupportforconductingthisreviewwasprovidedby
a Canadian Institutes of Health Research (CIHR) Frederick
Banting and Charles Best Canada Graduate Scholarship—
Master’sAwardreceivedbyEmilyJenkins.Theauthorswould
like to acknowledge and thank Dr. Denise Zabkiewicz for
her support throughout the development of this study and
Dr. Joy Johnson for her feedback during the early stages of
manuscript development.
References
[1] J. F. Greden, “The burden of disease for treatment-resistant
depression,” The Journal of Clinical Psychiatry, vol. 62, supple-
ment 16, pp. 26–31, 2001.
[2] H. A. Sackeim, “The deﬁnition and meaning of treatment-
resistantdepression,”TheJournalofClinicalPsychiatry,vol.62,
supplement 16, pp. 10–17, 2001.
[3] M. T. Berlim and G. Turecki, “Deﬁnition, assessment, and
staging of treatment-resistant refractory major depression: a6 Depression Research and Treatment
review of current concepts and methods,” Canadian Journal of
Psychiatry, vol. 52, no. 1, pp. 46–54, 2007.
[4] M. T. Berlim and G. Turecki, “What is the meaning of
treatment resistant/refractory major depression (TRD)? A
systematic review of current randomized trials,” European
Neuropsychopharmacology, vol. 17, no. 11, pp. 696–707, 2007.
[5] M. Fava, “Diagnosis and deﬁnition of treatment-resistant
depression,” Biological Psychiatry, vol. 53, no. 8, pp. 649–659,
2003.
[6] G. A. Fava, S. Fabbri, and N. Sonino, “Residual symptoms in
depression:anemergingtherapeutictarget,”ProgressinNeuro-
psychopharmacology and Biological Psychiatry,v o l .2 6 ,n o .6 ,
pp. 1019–1027, 2002.
[7] L. L. Judd, H. S. Akiskal, J. D. Maser et al., “Major depres-
sive disorder: a prospective study of residual subthreshold
depressive symptoms as predictor of rapid relapse,” Journal of
Aﬀective Disorders, vol. 50, no. 2-3, pp. 97–108, 1998.
[8] N.KennedyandE.S.Paykel,“Residualsymptomsatremission
from depression: impact on long-term outcome,” Journal of
Aﬀective Disorders, vol. 80, no. 2-3, pp. 135–144, 2004.
[9] P. Greenberg, P. K. Corey-Lisle, H. Birnbaum, M. Mary-
nchenko, and A. Claxton, “Economic implications of
treatment-resistant depression among employees,” Pharma-
coeconomics, vol. 22, no. 6, pp. 363–373, 2004.
[10] H. Arksey and L. O’Malley, “Scoping studies: towards a
methodological framework,” International Journal of Social
Research Methodology: Theory and Practice,v o l .8 ,n o .1 ,p p .
19–32, 2005.
[11] I. M. Anderson, A. Sarsﬁeld, and P. M. Haddad, “Eﬃcacy,
safety and tolerability of quetiapine augmentation in treat-
ment resistant depression: an open-label, pilot study,” Journal
of Aﬀective Disorders, vol. 117, no. 1-2, pp. 116–119, 2009.
[12] A. F. Carvalho, J. L. Cavalcante, M. S. Castelo, and M. C.
O. Lima, “Augmentation strategies for treatment-resistant
depression: a literature review,” Journal of Clinical Pharmacy
and Therapeutics, vol. 32, no. 5, pp. 415–428, 2007.
[13] R. W. Lam, P. Chan, M. Wilkins-Ho, and L. N. Yatham,
“Repetitive transcranial magnetic stimulation for treatment-
resistant depression: a systematic review and metaanalysis,”
Canadian Journal of Psychiatry, vol. 53, no. 9, pp. 621–631,
2008.
[14] S. Kito, K. Fujita, and Y. Koga, “Changes in regional cerebral
blood ﬂow after repetitive transcranial magnetic stimulation
of the left dorsolateral prefrontal cortex in treatment-resistant
depression,” Journal of Neuropsychiatry and Clinical Neuro-
sciences, vol. 20, no. 1, pp. 74–80, 2008.
[15] S. Kito, K. Fujita, and Y. Koga, “Regional cerebral blood ﬂow
changes after low-frequency transcranial magnetic stimula-
tion of the right dorsolateral prefrontal cortex in treatment-
resistant depression,” Neuropsychobiology, vol. 58, no. 1, pp.
29–36, 2008.
[16] S. Kito, T. Hasegawa, M. Okayasu et al., “Therapeutic eﬃcacy
of transcranial magnetic stimulation in treatment-resistant
depression: A three-dimensional stereotactic ROI template
(3DSRT) study,” Clinical Neurophysiology, vol. 120, no. 5,
article no. e153, 2009.
[17] S. Kito, T. Hasegawa, K. Fujita, and Y. Koga, “Changes
in hypothalamic-pituitary-thyroid axis following successful
treatment with low-frequency right prefrontal transcranial
magnetic stimulation in treatment-resistant depression,” Psy-
chiatry Research, vol. 175, no. 1-2, pp. 74–77, 2010.
[18] M. J. Burke and M. M. Husain, “Concomitant use of
vagus nerve stimulation and electroconvulsive therapy for
treatment-resistant depression,” Journal of Ect,v o l .2 2 ,n o .3 ,
pp. 218–222, 2006.
[19] W. Sperling, J. Kornhuber, J. Wiltfang, and S. Bleich, “Com-
bined VNS—rTMS treatment in a patient with therapy
resistant depression,” Pharmacopsychiatry,v o l .4 0 ,n o .1 ,p p .
39–40, 2007.
[ 2 0 ]M .M a e s ,I .M i h a y l o v a ,M .K u b e r a ,M .U y t t e r h o e v e n ,N .
Vrydags, and E. Bosmans, “Lower plasma Coenzyme Q10 in
depression: a marker for treatment resistance and chronic
fatigue in depression and a risk factor to cardiovascular
disorder in that illness,” Neuroendocrinology Letters, vol. 30,
no. 4, pp. 462–469, 2009.
[21] L. L. Carpenter, L. Bayat, F. Moreno et al., “Decreased cere-
brospinal ﬂuid concentrations of substance P in treatment-
resistant depression and lack of alteration after acute adjunct
vagusnervestimulationtherapy,”PsychiatryResearch,vol.157,
no. 1–3, pp. 123–129, 2008.
[22] L. A. Carvalho, B. A. Garner, T. Dew, H. Fazakerley, and C. M.
Pariante, “Antidepressants, but not antipsychotics, modulate
GR function in human whole blood: an insight into molecular
mechanisms,” European Neuropsychopharmacology, vol. 20,
no. 6, pp. 379–387, 2010.
[23] M. F. Juruena, C. M. Pariante, A. S. Papadopoulos, L. Poon,
S. Lightman, and A. J. Cleare, “Prednisolone suppression
test in depression: prospective study of the role of HPA
axis dysfunction in treatment resistance,” British Journal of
Psychiatry, vol. 194, no. 4, pp. 342–349, 2009.
[24] E. Watkins, J. Scott, J. Wingrove et al., “Rumination-focused
cognitive behaviour therapy for residual depression: a case
series,” Behaviour Research and Therapy,v o l .4 5 ,n o .9 ,p p .
2144–2154, 2007.
[25] M. Matsunaga, Y. Okamoto, S. I. Suzuki et al., “Psychosocial
functioning in patients with treatment-resistant depression
aftergroupcognitivebehavioraltherapy,”BMCPsychiatry,vol.
10, article no. 22, 2010.
[26] H. Viinam¨ aki, K. Haatainen, K. Honkalampi et al., “Which
factors are important predictors of non-recovery from major
depression? A 2-year prospective observational study,” Nordic
Journal of Psychiatry, vol. 60, no. 5, pp. 410–416, 2006.
[ 2 7 ]D .A m i t a l ,L .F o s t i c k ,A .S i l b e r m a n ,M .B e c k m a n ,a n dB .
Spivak, “Serious life events among resistant and non-resistant
MDD patients,” Journal of Aﬀective Disorders, vol. 110, no. 3,
pp. 260–264, 2008.
[28] E. Schramm, D. Schneider, I. Zobel et al., “Eﬃcacy of inter-
personal psychotherapy plus pharmacotherapy in chronically
depressed inpatients,” Journal of Aﬀective Disorders, vol. 109,
no. 1-2, pp. 65–73, 2008.
[29] N. J. Wiles, S. Hollinghurst, V. Mason et al., “A randomized
controlled trial of cognitive behavioural therapy as an adjunct
to pharmacotherapy in primary care based patients with
treatment resistant depression: a pilot study,” Behavioural and
Cognitive Psychotherapy, vol. 36, no. 1, pp. 21–33, 2008.
[30] G. S. Malhi, G. B. Parker, J. Crawford, K. Wilhelm, and
P. B. Mitchell, “Treatment-resistant depression: resistant to
deﬁnition?” Acta Psychiatrica Scandinavica, vol. 112, no. 4, pp.
302–309, 2005.
[31] M. T. Berlim, M. P. Fleck, and G. Turecki, “Current trends in
the assessment and somatic treatment of resistant/refractory
major depression: an overview,” Annals of Medicine, vol. 40,
no. 2, pp. 149–159, 2008.
[32] M. B. Keller, “Issues in treatment-resistant depression,” The
Journal of Clinical Psychiatry, vol. 66, supplement 8, pp. 5–12,
2005.Depression Research and Treatment 7
[33] B. N. Gaynes, L. Davis, A. J. Rush, M. Trivedi, M. Fava, and
S. R. Wisniewski, “The aims and design of the sequenced
treatment alternatives to relieve depression (STAR∗D) study,”
Primary Psychiatry, vol. 12, no. 2, pp. 36–41, 2005.
[34] D. Warden, A. J. Rush, M. H. Trivedi, M. Fava, and S. R.
Wisniewski, “The STAR∗D project results: a comprehensive
review of ﬁndings,” Current Psychiatry Reports,v o l .9 ,n o .6 ,
pp. 449–459, 2007.
[35] A.Fekadu,S.Wooderson,C.Donaldsonetal.,“Amultidimen-
sional tool to quantify treatment resistance in depression: the
Maudsley staging method,” The Journal of Clinical Psychiatry,
vol. 70, no. 2, pp. 177–184, 2009.
[36] A. J. Rush, J. Kilner, M. Fava et al., “Clinically relevant ﬁndings
from STAR∗D,” Psychiatric Annals, vol. 38, no. 3, pp. 188–193,
2008.
[37] S. Patten and H. Juby, A proﬁle of clinical depression in
Canada, Research Data Centre Netwo, Calgary, Canada, 2008,
https://dspace.ucalgary.ca/bitstream/1880/46327/6/Patten
RSS1.pdf.
[38] S. Schwartz, “Biological approaches to psychiatric disorders,”
in A Handbook for the Study of Mental Health,A .V .H o r w i t z
and T. L. Scheid, Eds., pp. 79–102, Cambridge University
Press, New York, NY, USA, 2006.
[39] C. I. Cohen, “The biomedicalization of psychiatry: a critical
overview,” Community Mental Health Journal,v o l .2 9 ,n o .6 ,
pp. 509–521, 1993.
[40] E. Schramm, D. Schneider, I. Zobel et al., “Eﬃcacy of inter-
personal psychotherapy plus pharmacotherapy in chronically
depressed inpatients,” Journal of Aﬀective Disorders, vol. 109,
no. 1-2, pp. 65–73, 2008.
[41] N. Bannan, “Multimodal therapy of treatment resistant
depression: a study and analysis,” International Journal of
Psychiatry in Medicine, vol. 35, no. 1, pp. 27–39, 2005.
[42] S. V. Parikh, R. W. Lam, and CANMAT Depression Work
Group, “Clinical practice guidelines: treatment of depressive
disorders,” Canadian Journal of Psychiatry, vol. 46, S1, pp. 5S–
76S, 2001.
[43] H. G. Ruh´ e ,G .v a nR o o i j e n ,J .S p i j k e r ,F .P .M .L .P e e t e r s ,
and A. H. Schene, “Staging methods for treatment resistant
depression. a systematic review,” Journal of Aﬀective Disorders,
2011.